<![CDATA[Hansa Biopharma — December 2022]]>Ja, god sætning :-), omkring AMR, så udtaler Hansa igår, at ud af ca. 3000 årlige AMR tilfælde går de efter de mest alvorlige og akutte, hvilket så måske er mellem 500-1000 tilfælde om året af 3mio. Skr. ,,Hvilket jo også er godt da 1mia. i overskud på en PE på 15 svarer til ca. godt 300 kurspoint

]]>https://dev.proinvestor.com/forum/topic/400733/hansa-biopharma-december-2022RSS for NodeSat, 06 Jun 2026 12:03:09 GMTThu, 01 Dec 2022 08:06:22 GMT60<![CDATA[Reply to Hansa Biopharma — December 2022 on Fri, 30 Dec 2022 05:04:45 GMT]]>Godmorgen 🙂

]]>https://dev.proinvestor.com/forum/post/8006431https://dev.proinvestor.com/forum/post/8006431Fri, 30 Dec 2022 05:04:45 GMT<![CDATA[Reply to Hansa Biopharma — December 2022 on Thu, 29 Dec 2022 05:37:16 GMT]]>Godmorgen 🙂

]]>https://dev.proinvestor.com/forum/post/8006432https://dev.proinvestor.com/forum/post/8006432Thu, 29 Dec 2022 05:37:16 GMT<![CDATA[Reply to Hansa Biopharma — December 2022 on Wed, 28 Dec 2022 07:58:05 GMT]]>God morgen 🙂

]]>https://dev.proinvestor.com/forum/post/8006435https://dev.proinvestor.com/forum/post/8006435Wed, 28 Dec 2022 07:58:05 GMT<![CDATA[Reply to Hansa Biopharma — December 2022 on Wed, 28 Dec 2022 06:55:51 GMT]]>god morgen

]]>https://dev.proinvestor.com/forum/post/8006433https://dev.proinvestor.com/forum/post/8006433Wed, 28 Dec 2022 06:55:51 GMT<![CDATA[Reply to Hansa Biopharma — December 2022 on Thu, 22 Dec 2022 05:12:37 GMT]]>Godmorgen 🙂

]]>https://dev.proinvestor.com/forum/post/8006427https://dev.proinvestor.com/forum/post/8006427Thu, 22 Dec 2022 05:12:37 GMT<![CDATA[Reply to Hansa Biopharma — December 2022 on Mon, 19 Dec 2022 05:32:43 GMT]]>Godmorgen 🙂

]]>https://dev.proinvestor.com/forum/post/8006429https://dev.proinvestor.com/forum/post/8006429Mon, 19 Dec 2022 05:32:43 GMT<![CDATA[Reply to Hansa Biopharma — December 2022 on Fri, 16 Dec 2022 05:07:15 GMT]]>Godmorgen 🙂

]]>https://dev.proinvestor.com/forum/post/8006434https://dev.proinvestor.com/forum/post/8006434Fri, 16 Dec 2022 05:07:15 GMT<![CDATA[Reply to Hansa Biopharma — December 2022 on Thu, 15 Dec 2022 05:12:32 GMT]]>Godmorgen 🙂

]]>https://dev.proinvestor.com/forum/post/8006424https://dev.proinvestor.com/forum/post/8006424Thu, 15 Dec 2022 05:12:32 GMT<![CDATA[Reply to Hansa Biopharma — December 2022 on Wed, 14 Dec 2022 07:01:20 GMT]]>Penser Play: Hansa Biopharma - Temadag Healthcare

(~30 min.)

]]>https://dev.proinvestor.com/forum/post/8006428https://dev.proinvestor.com/forum/post/8006428Wed, 14 Dec 2022 07:01:20 GMT<![CDATA[Reply to Hansa Biopharma — December 2022 on Wed, 14 Dec 2022 05:17:10 GMT]]>Godmorgen 🙂

]]>https://dev.proinvestor.com/forum/post/8006425https://dev.proinvestor.com/forum/post/8006425Wed, 14 Dec 2022 05:17:10 GMT<![CDATA[Reply to Hansa Biopharma — December 2022 on Tue, 13 Dec 2022 09:58:01 GMT]]>"Hansa has done a directed share issue adding SEK 420m in growth capital mainly supporting the US launch of Idifirix and to progress with an already extensive pipeline of opportunities ahead. A sizeable directed share issue directed to international institutions at a minimal rebate can be considered as a sign of strength in these market conditions."

Redeye er hurtigt ude med en lynanalyse. Redeye gør det altså godt.

]]>https://dev.proinvestor.com/forum/post/8006422https://dev.proinvestor.com/forum/post/8006422Tue, 13 Dec 2022 09:58:01 GMT<![CDATA[Reply to Hansa Biopharma — December 2022 on Tue, 13 Dec 2022 09:57:49 GMT]]>Hansa Biopharma: Adding growth capital ahead of the US launch

Just a moment...

favicon

(www.redeye.se)

]]>https://dev.proinvestor.com/forum/post/8006426https://dev.proinvestor.com/forum/post/8006426Tue, 13 Dec 2022 09:57:49 GMT<![CDATA[Reply to Hansa Biopharma — December 2022 on Tue, 13 Dec 2022 08:37:00 GMT]]>Braidwell har også haft en heldig (22. november 22) hånd mht. Compass Therapeutics:

Link Preview Image
Compass Therapeutics Announces $80 Million Private Placement

BOSTON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), (“Compass”), a clinical-stage biopharmaceutical company developing...

favicon

GlobeNewswire News Room (www.globenewswire.com)

... som er oppe med +116% de seneste 6 måneder.

]]>https://dev.proinvestor.com/forum/post/8006423https://dev.proinvestor.com/forum/post/8006423Tue, 13 Dec 2022 08:37:00 GMT<![CDATA[Reply to Hansa Biopharma — December 2022 on Tue, 13 Dec 2022 07:42:02 GMT]]>samt nye store amerikanske investorer inde super 🙂

]]>https://dev.proinvestor.com/forum/post/8006430https://dev.proinvestor.com/forum/post/8006430Tue, 13 Dec 2022 07:42:02 GMT<![CDATA[Reply to Hansa Biopharma — December 2022 on Tue, 13 Dec 2022 07:41:30 GMT]]>En super nyhed nu er der penge i kassen og tydligt at se på kursen der er fjernet en usikkerhed 🙂

]]>https://dev.proinvestor.com/forum/post/8006419https://dev.proinvestor.com/forum/post/8006419Tue, 13 Dec 2022 07:41:30 GMT<![CDATA[Reply to Hansa Biopharma — December 2022 on Tue, 13 Dec 2022 07:30:42 GMT]]>Ja, det er MEGET positivt 🙂 Meget bedre end kraftig udvanding til eksisterende aktionærer,
til en eller anden lav kurs.

]]>https://dev.proinvestor.com/forum/post/8006417https://dev.proinvestor.com/forum/post/8006417Tue, 13 Dec 2022 07:30:42 GMT<![CDATA[Reply to Hansa Biopharma — December 2022 on Tue, 13 Dec 2022 07:23:31 GMT]]>Ret imponerende, at den rettede emi gennemføres stort set til dagskursen.

]]>https://dev.proinvestor.com/forum/post/8006421https://dev.proinvestor.com/forum/post/8006421Tue, 13 Dec 2022 07:23:31 GMT<![CDATA[Reply to Hansa Biopharma — December 2022 on Tue, 13 Dec 2022 07:05:42 GMT]]>Hansa avser att använda nettolikviden från den riktade nyemissionen för att påbörja förberedelser för en potentiell lansering av imlifidase i USA för njurtransplantation, stärka pågående produktutvecklingsaktiviteter och utvidga bolagets forsknings- och utvecklingspipeline.

]]>https://dev.proinvestor.com/forum/post/8006420https://dev.proinvestor.com/forum/post/8006420Tue, 13 Dec 2022 07:05:42 GMT<![CDATA[Reply to Hansa Biopharma — December 2022 on Tue, 13 Dec 2022 07:02:57 GMT]]>Den befintliga institutionella investeraren Redmile Group och den nya amerikanska institutionella investeraren Braidwell samt andra amerikanska och internationella institutionella investerare deltog i den riktade nyemissionen.

]]>https://dev.proinvestor.com/forum/post/8006416https://dev.proinvestor.com/forum/post/8006416Tue, 13 Dec 2022 07:02:57 GMT<![CDATA[Reply to Hansa Biopharma — December 2022 on Tue, 13 Dec 2022 07:02:34 GMT]]>HANSA BIOPHARMA: RIKTAD EMISSION 416 MLN KR, PRIS 53 KR/AKTIE

]]>https://dev.proinvestor.com/forum/post/8006415https://dev.proinvestor.com/forum/post/8006415Tue, 13 Dec 2022 07:02:34 GMT<![CDATA[Reply to Hansa Biopharma — December 2022 on Tue, 13 Dec 2022 05:28:22 GMT]]>Godmorgen 🙂

]]>https://dev.proinvestor.com/forum/post/8006414https://dev.proinvestor.com/forum/post/8006414Tue, 13 Dec 2022 05:28:22 GMT<![CDATA[Reply to Hansa Biopharma — December 2022 on Mon, 12 Dec 2022 05:20:17 GMT]]>Godmorgen 🙂

]]>https://dev.proinvestor.com/forum/post/8006418https://dev.proinvestor.com/forum/post/8006418Mon, 12 Dec 2022 05:20:17 GMT<![CDATA[Reply to Hansa Biopharma — December 2022 on Fri, 09 Dec 2022 20:22:44 GMT]]>Så mangler vi kun Spanien fra "The Big Five". Iflg. Søren T., så venter de afgørelse omkring q2/q3 2023

]]>https://dev.proinvestor.com/forum/post/8006410https://dev.proinvestor.com/forum/post/8006410Fri, 09 Dec 2022 20:22:44 GMT<![CDATA[Reply to Hansa Biopharma — December 2022 on Fri, 09 Dec 2022 16:33:19 GMT]]>Analyskommentar (8 Dec 2022) fra Penser:

https://epaccess.penser.se/analys/analyskommentar-kostnadsersattning-pa-plats-i-italien/

"Vi ser givetvis positivt på denna nyhet och konstaterar även att nästan samtliga större länder i Europa har valt att kostnadsersätta Idefirix (vi väntar på beslut från Spanien)."

]]>https://dev.proinvestor.com/forum/post/8006411https://dev.proinvestor.com/forum/post/8006411Fri, 09 Dec 2022 16:33:19 GMT